1. Home
  2. IHG vs EXAS Comparison

IHG vs EXAS Comparison

Compare IHG & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intercontinental Hotels Group

IHG

Intercontinental Hotels Group

HOLD

Current Price

$140.55

Market Cap

21.5B

ML Signal

HOLD

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$103.35

Market Cap

19.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IHG
EXAS
Founded
1777
1995
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.5B
19.7B
IPO Year
2000
2000

Fundamental Metrics

Financial Performance
Metric
IHG
EXAS
Price
$140.55
$103.35
Analyst Decision
Hold
Hold
Analyst Count
3
18
Target Price
N/A
$85.64
AVG Volume (30 Days)
236.1K
2.1M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
1.19%
N/A
EPS Growth
N/A
80.32
EPS
N/A
N/A
Revenue
N/A
$4,144,000.00
Revenue This Year
$9.51
$15.18
Revenue Next Year
$5.62
$12.46
P/E Ratio
$29.84
N/A
Revenue Growth
N/A
N/A
52 Week Low
$94.78
$38.88
52 Week High
$150.89
$103.87

Technical Indicators

Market Signals
Indicator
IHG
EXAS
Relative Strength Index (RSI) 46.62 65.17
Support Level $133.08 $101.12
Resistance Level $144.96 $103.87
Average True Range (ATR) 3.30 0.33
MACD -0.60 -0.13
Stochastic Oscillator 5.23 66.15

Price Performance

Historical Comparison
IHG
EXAS

About IHG Intercontinental Hotels Group

InterContinental Hotels Group operates 987,000 rooms across 20 brands addressing the midscale through luxury segments, as of Dec. 31, 2024. Holiday Inn and Holiday Inn Express constitute the largest brand, while Hotel Indigo, Even, Hualuxe, Kimpton, and Voco are newer lifestyle brands experiencing strong demand. The company launched a midscale brand, Avid, in 2017 and closed on a 51% stake in Regent Hotels in 2018. It acquired Six Senses in 2019 and launched another midscale brand, Garner, in 2023. Managed and franchised represent 99% of total rooms. As of Dec. 31, 2024, the Americas represented 53% of total rooms, with Greater China accounting for 20% and Europe, Asia, the Middle East, and Africa making up 27%.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: